SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 12/21/2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that results of pre-clinical studies with telavancin were recently presented at the 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington, D.C.
Telavancin is a novel lipoglycopeptide injectable antibiotic discovered by Theravance that is currently in development for serious Gram-positive infections including those caused by drug-resistant Staphylococcus aureus strains. Previously presented data demonstrated that telavancin has a unique multifunctional mechanism of action that the company believes results in enhanced bacterial killing and may help reduce the risk of inducing resistance. Telavancin is currently being evaluated in Phase 3 studies for its safety and efficacy in the treatment of complicated skin and skin structure infections and hospital-acquired pneumonia.
